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BACKGROUND
Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase 
(PARP), has been associated with significantly increased progression-free survival 
among patients with recurrent ovarian cancer after platinum-based chemotherapy, 
regardless of the presence or absence of BRCA mutations. The efficacy of niraparib 
in patients with newly diagnosed advanced ovarian cancer after a response to first-
line platinum-based chemotherapy is unknown.
METHODS
In this randomized, double-blind, phase 3 trial, we randomly assigned patients with 
newly diagnosed advanced ovarian cancer in a 2:1 ratio to receive niraparib or pla-
cebo once daily after a response to platinum-based chemotherapy. The primary end 
point was progression-free survival in patients who had tumors with homologous-
recombination deficiency and in those in the overall population, as determined on 
hierarchical testing. A prespecified interim analysis for overall survival was con-
ducted at the time of the primary analysis of progression-free survival.
RESULTS
Of the 733 patients who underwent randomization, 373 (50.9%) had tumors with 
homologous-recombination deficiency. Among the patients in this category, the me-
dian progression-free survival was significantly longer in the niraparib group than in 
the placebo group (21.9 months vs. 10.4 months; hazard ratio for disease progression 
or death, 0.43; 95% confidence interval [CI], 0.31 to 0.59; P<0.001). In the overall 
population, the corresponding progression-free survival was 13.8 months and 
8.2 months (hazard ratio, 0.62; 95% CI, 0.50 to 0.76; P<0.001). At the 24-month interim 
analysis, the rate of overall survival was 84% in the niraparib group and 77% in the 
placebo group (hazard ratio, 0.70; 95% CI, 0.44 to 1.11). The most common adverse 
events of grade 3 or higher were anemia (in 31.0% of the patients), thrombocytopenia 
(in 28.7%), and neutropenia (in 12.8%). No treatment-related deaths occurred.
CONCLUSIONS
Among patients with newly diagnosed advanced ovarian cancer who had a response to 
platinum-based chemotherapy, those who received niraparib had significantly longer 
progression-free survival than those who received placebo, regardless of the presence 
or absence of homologous-recombination deficiency. (Funded by GlaxoSmithKline; 
PRIMA/ENGOT-OV26/GOG-3012 ClinicalTrials.gov number, NCT02655016.)
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Ovarian cancer is a leading cause of death from gynecologic cancers in women worldwide.1 The standard treat-
ment for newly diagnosed advanced epithelial 
ovarian cancer is surgical cytoreduction and 
systemic platinum–taxane combination chemo-
therapy. Unfortunately, up to 85% of the patients 
with advanced ovarian cancer have a disease re-
currence after completing chemotherapy.
In these patients, bevacizumab can be added 
to chemotherapy, followed by bevacizumab main-
tenance therapy. However, the use of bevacizu-
mab is limited because of safety concerns, and 
data are lacking on its use in the growing num-
ber of patients who receive neoadjuvant chemo-
therapy.2,3 Olaparib, an inhibitor of poly(adenosine 
diphosphate [ADP]–ribose) (PARP), has been asso-
ciated with longer progression-free survival than 
placebo among patients with BRCA-mutated tu-
mors, which includes approximately 15 to 20% of 
the patients with ovarian cancer, after a response 
to first-line platinum-based chemotherapy.4 There-
fore, most patients with advanced ovarian can-
cer do not have an effective treatment option to 
substantially reduce the risk of death or progres-
sive disease after first-line chemotherapy.5,6
Niraparib is an oral, highly selective PARP1 
and PARP2 inhibitor that has been approved as 
maintenance therapy in patients with recurrent 
ovarian cancer who have had a response to 
platinum-based chemotherapy. Niraparib has 
shown efficacy both in patients who have tu-
mors with BRCA mutations and in those without 
BRCA mutations.7,8 In the NOVA (ENGOT-OV16/
NOVA) trial,7 patients who received niraparib 
had significantly longer progression-free survival 
than those who received placebo in all the co-
horts, including in patients with germline BRCA 
mutations (21.0 months vs. 5.5 months; hazard 
ratio, 0.27; P<0.001) and in those without germ-
line BRCA mutations (9.3 months vs. 3.9 months; 
hazard ratio, 0.45; P<0.001). The NOVA trial also 
tested the efficacy of niraparib according to 
homologous-recombination status in patients 
without BRCA mutations and showed a benefit 
regardless of homologous-recombination status. 
(Although a deleterious BRCA mutation indicates 
that a tumor has some form of homologous-
recombination deficiency, patterns of genomic 
instability in the tumor can confer such a pheno-
type in the absence of a BRCA mutation.) The 
primary objective of the PRIMA (PRIMA/ENGOT-
OV26/GOG-3012) trial was to test the efficacy 
and safety of niraparib maintenance therapy after 
a response to platinum-based chemotherapy in 
patients with newly diagnosed advanced ovarian 
cancer at high risk for relapse.
Me thods
Patients
Eligible patients were at least 18 years of age and 
had newly diagnosed, histologically confirmed 
advanced cancer of the ovary, peritoneum, or 
fallopian tube (collectively defined as ovarian 
cancer). All the patients had high-grade serous 
or endometrioid tumors that were classified as 
stage III or IV, according to the criteria of the 
International Federation of Gynecology and Ob-
stetrics. Included in this category were patients 
with stage III disease with visible residual tumor 
after primary debulking surgery, inoperable stage 
III disease, or any stage IV disease, as well as 
those who had received neoadjuvant chemo-
therapy.
Before enrollment, all the patients had received 
six to nine cycles of first-line platinum-based 
chemotherapy, which had resulted in a complete 
or partial response, according to investigator 
assessment. Tumor samples underwent central 
testing to identify those with homologous- 
recombination deficiency (myChoice test, Myriad 
Genetics). Homologous-recombination deficiency 
was defined as the presence of a BRCA deleteri-
ous mutation, a score of at least 42 on the my-
Choice test,9-11 or both. Test scores (which range 
from 1 to 100, with higher scores indicating a 
greater number of genomic abnormalities) repre-
sent a continuum on the basis of loss of hetero-
zygosity, telomeric allelic imbalance, and large-
scale state transitions. Additional details regarding 
testing for homologous-recombination deficiency 
are provided in the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org.
Patients in whom status regarding homolo-
gous-recombination deficiency was not determined 
were eligible to participate in the trial and were 
included in the overall population. All the pa-
tients provided written informed consent. Fur-
ther details and eligibility criteria are provided 
in the Supplementary Appendix.
Trial Oversight
The trial was performed in accordance with the 
principles of the Declaration of Helsinki, Good 
A Quick Take is 
available at 
NEJM.org 
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Clinical Practices, and all local laws under the 
auspices of an independent data and safety moni-
toring committee. The trial was designed by the 
sponsor, GlaxoSmithKline, in collaboration with 
the European Network for Gynecological Onco-
logical Trial (ENGOT) groups and the coopera-
tive group leadership of GOG Partners (a com-
ponent of the Gynecologic Oncology Group 
Foundation), according to the ENGOT model C.12 
The sponsor was responsible for overseeing the 
collection, analysis, and interpretation of the 
data. All the authors had full access to the trial 
data. The authors wrote the manuscript, with 
medical writing assistance funded by the spon-
sor. All the authors attest to the accuracy and 
completeness of the data and the fidelity of the 
trial to the protocol, available at NEJM.org.
Trial Design and Treatment
This randomized, double-blind, placebo-controlled 
phase 3 trial was conducted in 20 countries at 
181 clinical sites. (Details regarding the clinical 
sites are provided in Table S1 in the Supplemen-
tary Appendix.) Within 12 weeks after comple-
tion of the last dose of platinum-based chemo-
therapy, the patients were randomly assigned in 
a 2:1 ratio to receive oral niraparib or placebo 
once daily in 28-day cycles for 36 months or 
until disease progression. In the initial protocol, 
all the patients started at a fixed dose of 300 mg 
once daily. The trial was amended on November 
27, 2017, to incorporate an individualized start-
ing dose of 200 mg once daily for patients with 
a baseline body weight of less than 77 kg, a plate-
let count of less than 150,000 per cubic millimeter, 
or both.13
Randomization was performed in a double-
blind manner with the use of an interactive Web-
response system, with stratification according to 
clinical response after first-line platinum-based 
chemotherapy (complete or partial response), re-
ceipt of neoadjuvant chemotherapy (yes or no), 
and status regarding tumor homologous recombi-
nation (deficient vs. proficient or not determined).
Niraparib or placebo was administered con-
tinuously until the objective identification of 
disease progression on imaging, provided that 
the patient was receiving benefit and did not 
meet any other criteria for discontinuation, as 
defined in the protocol. Adverse events were 
graded according to the National Cancer Insti-
tute Common Terminology Criteria for Adverse 
Events, version 4.03. Indications for treatment 
interruptions and dose reductions were defined 
in the protocol. (The schedule of dose reductions 
is provided in Tables S3 and S4.) Patients receiv-
ing placebo were not allowed to cross over to 
receive niraparib treatment during the trial.
Assessments
We performed computed tomography or mag-
netic resonance imaging to assess progressive 
disease every 12 weeks until treatment discon-
tinuation. The objective assessment of progres-
sive disease was determined by central radio-
logic and clinical review in a blinded manner, 
according to RECIST (Response Evaluation Cri-
teria in Solid Tumors), version 1.1.14 Clinical 
progression was reviewed if an increased CA125 
level was accompanied by histologic proof or 
clinical symptoms, as specified in the protocol. 
We administered the Functional Assessment of 
Cancer Therapy–Ovarian Symptom Index (FOSI),15 
the European Quality of Life five-dimension, 
five-level questionnaire (EQ-5D-5L),16 the Euro-
pean Organization for Research and Treatment 
of Cancer (EORTC) Quality of Life Questionnaire 
(EORTC-QLQ-C30),17 and the EORTC Quality 
of Life Questionnaire Ovarian Cancer module 
(EORTC-QLQ-OV28)18 at the screening visit, 
throughout treatment, and 4, 8, 12, and 24 
weeks after the last dose of niraparib or placebo. 
(Details regarding the trial assessments, includ-
ing monitoring of adverse events, are provided in 
the Supplementary Appendix.)
End Points
The primary end point was progression-free sur-
vival in patients who had tumors with homolo-
gous-recombination deficiency and in those in 
the overall population, as determined on hierarchi-
cal testing. This end point was evaluated in a 
time-to-event analysis and was assessed by blind-
ed independent central review. Progression-free 
survival was defined as the time from randomiza-
tion after completion of platinum-based chemo-
therapy to the earliest date of objective disease 
progression on imaging (according to RECIST, 
version 1.1) or death from any cause. An inde-
pendent radiologic review and central clinician 
review that were conducted in a blinded manner 
were used to define the date of disease progres-
sion, and an identical schedule of assessments 
was used for the two trial groups.
Overall survival was a key secondary end 
point. Other secondary end points were the time 
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until the first subsequent therapy, progression-free 
survival 2 (defined as time from randomization 
to progression while the patient was receiving a 
subsequent anticancer therapy), pharmacokinetic 
analyses, and patient-reported outcomes (scores 
on the FOSI, EQ-5D-5L, and EORTC-QLQ-C30/
OV28 instruments). Safety was assessed through 
the monitoring of adverse events, laboratory test-
ing, measurement of vital signs, and physical 
examination.
Statistical Analysis
We determined that the enrollment of at least 
620 patients (including 310 patients who had 
tumors with homologous-recombination defi-
ciency) would provide a power of more than 90% 
to detect a significant difference in progression-
free survival between niraparib and placebo at a 
one-sided type I error of 0.025.19,20 These criteria 
corresponded to a hazard ratio for disease pro-
gression or death of 0.50 in the group with 
homologous-recombination deficiency and 0.65 
in the overall population of all the patients who 
had undergone randomization.
A hierarchical-testing method was performed 
for the primary end point in the population with 
homologous-recombination deficiency, followed 
by a test in the overall population. At the time of 
the trial design, consideration of the reported 
median duration of progression-free survival for 
patients with ovarian cancer with a BRCA muta-
tion who received placebo led to an estimated 
median duration of progression-free survival of 
21 months in the patients with homologous-
recombination deficiency and 14 months in the 
overall population for the sample-size estima-
tion. Additional details regarding the statistical 
analysis are provided in the Supplementary Ap-
pendix.
R esult s
Patients
From July 2016 through June 2018, a total of 733 
patients underwent randomization. Five patients 
who did not receive either niraparib or placebo 
after randomization were excluded from the safe-
ty analysis. As of the data cutoff on May 17, 2019, 
a total of 246 patients were still receiving treat-
ment with niraparib or placebo (Fig. 1).
The demographic and clinical characteristics 
of the patients at baseline were balanced in the 
two trial groups (Table 1). The overall popula-
tion included patients at high risk for progres-
sive disease as a result of stage III ovarian cancer 
with residual disease after primary debulking 
surgery (23.1%), receipt of neoadjuvant chemo-
therapy (66.7%), stage IV ovarian cancer (35.0%), 
or a partial response to first-line platinum-based 
chemotherapy (30.5%). Of the 733 patients who 
had undergone randomization, 373 (50.9%) had 
tumors with homologous-recombination deficien-
cy on myChoice testing; among these patients, 
223 had tumors with BRCA mutations, and 150 
had tumors without BRCA mutations (Fig. S1).
Efficacy
The primary efficacy analysis was performed 
after disease progression or death had occurred 
in 154 patients with homologous-recombination 
deficiency and in 386 patients in the overall 
population. The median duration of follow-up at 
the time of the data cutoff was 13.8 months 
(range, <1.0 to 28.0). The median relative dose 
intensity (the proportion of administered doses 
relative to planned doses) was 63% for niraparib 
and 99% for placebo.
The median duration of progression-free sur-
vival in patients with homologous-recombination 
deficiency was 21.9 months with niraparib and 
10.4 months with placebo (hazard ratio for dis-
ease progression or death, 0.43; 95% confidence 
interval [CI], 0.31 to 0.59; P<0.001) (Fig. 2A). In 
the overall population, the median duration of 
progression-free survival was 13.8 months with 
niraparib and 8.2 months with placebo (hazard 
ratio, 0.62; 95% CI, 0.50 to 0.76; P<0.001) 
(Fig. 2B).
In the interim analysis of the key secondary 
end point of overall survival (performed after the 
deaths of 79 of 733 patients [10.8%] in the over-
all population), the estimated Kaplan–Meier 
probability of survival at 24 months was 84% in 
the niraparib group and 77% in the placebo 
group (hazard ratio for death, 0.70; 95% CI, 0.44 
to 1.11). In the population with homologous- 
recombination deficiency, the interim analysis 
showed an estimated probability of 24-month 
survival of 91% in the niraparib group and 85% 
in the placebo group (hazard ratio, 0.61; 95% CI, 
0.27 to 1.39). Additional details regarding the 
secondary end points are provided in Table S5.
The results of prespecified exploratory analyses 
are provided in Figure 3 and Table S6. Within 
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the population with homologous-recombination 
deficiency, the median duration of progression-
free survival was 22.1 months in the niraparib 
group and 10.9 months in the placebo group 
(hazard ratio, 0.40; 95% CI, 0.27 to 0.62) in the 
subgroup with BRCA mutations and 19.6 months 
and 8.2 months, respectively (hazard ratio, 0.50; 
95% CI, 0.31 to 0.83), in the subgroup without 
Figure 1. Enrollment and Outcomes in the Two Primary Populations.
In the PRIMA trial, the primary end point was progression-free survival in patients who had tumors with homologous-
recombination deficiency and in those in the overall population, as determined on hierarchical testing. The primary 
end point was first tested in patients who had tumors with homologous-recombination deficiency (who were thought 
to have an increased benefit with niraparib) and then in the overall population to test the benefit in all the patients. 
Patients who had undetermined status with regard to homologous recombination were included in the subgroup 
with homologous-recombination proficiency.
733 Underwent randomization
989 Patients were assessed for eligibility
256 Were ineligible
484 Received niraparib
245 Had homologous-recombination
deficiency
239 Had homologous-recombination
proficiency
244 Received placebo
125 Had homologous-recombination
deficiency
119 Had homologous-recombination
proficiency 
307 Discontinued niraparib
among all 484 patients
58 Had adverse event
218 Had progressive
disease
12 Withdrew
19 Had other reasons
124 Discontinued niraparib
among 245 patients with
homologous-recombination
deficiency
27 Had adverse event
80 Had progressive
disease
8 Withdrew
9 Had other reasons
175 Discontinued placebo
among all 244 patients 
5 Had adverse event
162 Had progressive
disease
1  Withdrew
7 Had other reasons
83 Discontinued placebo
among 125 patients with
homologous-recombination
deficiency
2 Had adverse event
76 Had progressive
disease
5 Had other reasons
177 Were still receiving niraparib at data
cutoff
121 Had homologous-recombination
 deficiency
56 Had homologous-recombination
proficiency
69  Were still receiving placebo at data
cutoff
42 Had homologous-recombination
deficiency
27 Had homologous-recombination
proficiency
3 Did not receive niraparib 2 Did not receive placebo
246 Were assigned to receive
placebo
487 Were assigned to receive
niraparib
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Characteristic Niraparib Placebo
HRD Population 
(N = 247)
Overall Population 
(N = 487)
HRD Population 
(N = 126)
Overall Population 
(N = 246)
Median age (range) — yr 58 (32–83) 62 (32–85) 58 (33–82) 62 (33–88)
ECOG score — no. (%)†
0 182 (73.7) 337 (69.2) 97 (77.0) 174 (70.7)
1 65 (26.3) 150 (30.8) 29 (23.0) 72 (29.3)
International FIGO stage — no. (%)‡
III 161 (65.2) 318 (65.3) 78 (61.9) 158 (64.2)
A 4 (1.6) 7 (1.4) 1 (0.8) 4 (1.6)
B 10 (4.0) 16 (3.3) 9 (7.1) 12 (4.9)
C 140 (56.7) 285 (58.5) 67 (53.2) 138 (56.1)
Not specified 7 (2.8) 10 (2.1) 1 (0.8) 4 (1.6)
IV 86 (34.8) 169 (34.7) 48 (38.1) 88 (35.8)
Primary tumor location — no. (%)
Ovary 201 (81.4) 388 (79.7) 105 (83.3) 201 (81.7)
Fallopian tube 32 (13.0) 65 (13.3) 13 (10.3) 32 (13.0)
Peritoneum 14 (5.7) 34 (7.0) 8 (6.3) 13 (5.3)
Histologic type — no. (%)§
Serous 234 (94.7) 465 (95.5) 116 (92.1) 230 (93.5)
Endometrioid 5 (2.0) 11 (2.3) 6 (4.8) 9 (3.7)
Other 8 (3.2) 11 (2.3) 4 (3.2) 6 (2.4)
Receipt of neoadjuvant chemotherapy — no. (%)
Yes 156 (63.2) 322 (66.1) 80 (63.5) 167 (67.9)
No 91 (36.8) 165 (33.9) 46 (36.5) 79 (32.1)
Clinical response after platinum-based 
chemo therapy — no. (%)
Complete response 185 (74.9) 337 (69.2) 93 (73.8) 172 (70.0)
Partial response 62 (25.1) 150 (30.8) 33 (26.2) 74 (30.0)
Cancer antigen 125 level — no. (%)
≤ULN 236 (95.5) 450 (92.4) 120 (95.2) 226 (91.9)
>ULN 9 (3.6) 34 (7.0) 5 (4.0) 18 (7.3)
Missing data 2 (0.8) 3 (0.6) 1 (0.8) 2 (0.8)
No. of cycles of platinum-based chemotherapy 
— no. (%)
6 165 (66.8) 333 (68.4) 84 (66.7) 170 (69.1)
7–9 52 (21.1) 124 (25.5) 28 (22.2) 62 (25.2)
Missing data 30 (12.1) 30 (6.2) 14 (11.1) 14 (5.7)
*  Percentages may not total 100 because of rounding. HRD denotes homologous-recombination deficiency, and ULN upper limit of the nor-
mal range.
†  According to the Eastern Cooperative Oncology Group (ECOG) performance-status evaluation, a score of 0 indicates that the patient is fully 
active and able to carry on all predisease performance without restriction, and a score of 1 indicates that the patient is restricted in physical-
ly strenuous activity but ambulatory and able to carry out work of a light or sedentary nature.
‡  Details regarding staging criteria according to the International Federation of Gynecology and Obstetrics (FIGO) guidelines are provided in 
Table S2 in the Supplementary Appendix.
§  Histologic data for one patient were missing, but a serous tumor was identified on cytologic analysis.
Table 1. Characteristics of the Patients at Baseline.*
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BRCA mutations. In the subgroup of patients 
with homologous-recombination proficiency, the 
median duration of progression-free survival was 
8.1 months in the niraparib group and 5.4 months 
in the placebo group (hazard ratio, 0.68; 95% CI, 
0.49 to 0.94). In this population, the interim 
Figure 2. Progression-free Survival in the Two Primary Populations.
Shown are Kaplan–Meier estimates of progression-free survival in the niraparib group and the placebo group among 
the patients who had tumors with homologous-recombination deficiency (Panel A) and in those in the overall popu-
lation (Panel B), according to central review. The horizontal dashed line indicates the median value. Asterisks and 
circles indicate censored data.
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overall survival analysis showed an estimated 
probability of survival at 24 months of 81% in 
the niraparib group and 59% in the placebo 
group (hazard ratio, 0.51; 95% CI, 0.27 to 0.97).
In addition to the subgroup of patients who 
had tumors with homologous-recombination pro-
ficiency, the treatment effect of niraparib ex-
tended to patients with advanced ovarian cancer 
in other subgroups with a poor prognosis, includ-
ing in those who received neoadjuvant chemo-
therapy (13.9 vs. 8.2 months; hazard ratio, 0.59; 
95% CI, 0.46 to 0.76) and in those with a partial 
response to platinum-based chemotherapy (8.3 vs. 
5.6 months; hazard ratio, 0.60; 95% CI, 0.43 to 
0.85). Niraparib was also associated with a longer 
duration of progression-free survival than placebo 
in the patients who had a complete response to 
chemotherapy (16.4 months vs. 9.5 months; haz-
ard ratio, 0.60; 95% CI, 0.46 to 0.77). The results 
of a sensitivity analysis of progression-free sur-
vival were similar to and supported the blinded 
analysis on independent central review (Table S7).
Safety
Common adverse events that occurred during the 
trial are listed in Table 2 and Table S9. Among 
the most common grade 3 or higher adverse 
events in the niraparib group were anemia (in 
31.0% of the patients), thrombocytopenia (in 
28.7%), and neutropenia (in 12.8%). Dose reduc-
tions were conducted in 70.9% of the patients in 
the niraparib group. The frequency of treatment 
discontinuation because of adverse events was 
12.0% in the niraparib group and 2.5% in the 
placebo group. Myelosuppressive adverse events 
were the main reason for discontinuation but 
Figure 3. Disease Progression or Death, According to Prespecified Subgroups.
Shown is the incidence of disease progression or death, according to the listed subgroups, in the two trial groups. On the Eastern Cooperative 
Oncology Group (ECOG) performance-status evaluation, a score of 0 indicates that the patient is fully active and able to carry on all predisease 
performance without restriction, and a score of 1 indicates that the patient is restricted in physically strenuous activity but ambulatory and able 
to carry out work of a light or sedentary nature. The vertical shading indicates the 95% confidence interval for the overall population.
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or death/total no. (%)
232/487 (47.6) 155/246 (63.0)
136/297 (45.8) 86/147 (58.5) 0.61 (0.47–0.81)
96/190 (50.5) 69/99 (69.7) 0.53 (0.38–0.74)
146/337 (43.3) 107/174 (61.5) 0.60 (0.46–0.77)
86/150 (57.3) 48/72 (66.7) 0.69 (0.48–1.00)
 
143/318 (45.0) 103/158 (65.2) 0.54 (0.42–0.70)
89/169 (52.7) 52/88 (59.1) 0.79 (0.55–1.12)
151/322 (46.9) 107/167 (64.1) 0.59 (0.46–0.76)
81/165 (49.1) 48/79 (60.8) 0.66 (0.46–0.94)
146/337 (43.3) 100/172 (58.1) 0.60 (0.46–0.77)
86/150 (57.3) 55/74 (74.3) 0.60 (0.43–0.85)
104/218 (47.7) 82/115 (71.3) 0.50 (0.37–0.68)
128/269 (47.6) 73/131 (55.7) 0.72 (0.54–0.96)
49/152 (32.2) 40/71 (56.3) 0.40 (0.27–0.62)
111/169 (65.7) 56/80 (70.0) 0.68 (0.49–0.94)
 32/95 (33.7) 33/55 (60.0) 0.50 (0.31–0.83)
40/71 (56.3) 26/40 (65.0)
0.62 (0.50–0.76)
0.85 (0.51–1.43)
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were infrequent (4.3% for thrombocytopenia in 
the niraparib group) (Table S8). One case of my-
elodysplastic syndrome was identified in a pa-
tient in the niraparib group. Low-grade nausea 
and fatigue were common in the two groups. No 
deaths during treatment with niraparib were 
reported during the trial. Safety improved with 
the implementation of the individualized dosing 
regimen (Tables S10 and S11).
Patient-Reported Outcomes
The analysis of patient-reported outcomes did not 
indicate a between-group difference in health-
related quality-of-life scores (Fig. S2). Survey 
completion rates were high and were similar in 
the two groups (Table S12).
Discussion
In the PRIMA trial, we found that patients with 
newly diagnosed advanced ovarian cancer who 
received niraparib after having a response to 
first-line platinum-based chemotherapy had sig-
nificantly longer progression-free survival than 
those who received placebo in the overall popu-
lation. No new safety signals were identified for 
niraparib.
Historically, clinical activity with PARP in-
hibitors has been associated with the presence 
of BRCA mutations, with most studies conducted 
in this selected patient population. Recent non-
clinical studies,21 together with the NOVA7 and 
QUADRA8 clinical trials, have shown the effec-
tiveness of niraparib in treating patients with 
wild-type BRCA tumors. In the PRIMA trial, our 
primary hypothesis was that the clinical benefit 
of first-line treatment with niraparib could be 
extended to all patients with advanced ovarian 
cancer, including those who had tumors with 
homologous-recombination deficiency (with either 
mutated or unmutated BRCA) and those with 
homologous-recombination proficiency. Results 
of this trial confirm the hypothesis that treat-
ment with niraparib provides a longer duration 
of progression-free survival than placebo in the 
overall population. Currently, the most common 
treatment strategy with these patients is active 
surveillance. Preliminary results of the interim 
analysis suggest that overall survival may also be 
improved, but the data are not sufficiently ma-
ture to assess this end point with precision.
The high-risk patients with advanced ovarian 
cancer who were included in this trial are gener-
Adverse Events Niraparib (N = 484) Placebo (N = 244)
no. of patients (%)
Overall population
Adverse event
Any 478 (98.8) 224 (91.8)
Grade ≥3 341 (70.5) 46 (18.9)
Treatment-related adverse event*
Any 466 (96.3) 168 (68.9)
Grade ≥3 316 (65.3) 16 (6.6)
Serious adverse event
Any 156 (32.2) 32 (13.1)
Treatment-related 118 (24.4) 6 (2.5)
Leading to treatment discontinuation 58 (12.0) 6 (2.5)
Leading to dose reduction 343 (70.9) 20 (8.2)
Leading to dose interruption 385 (79.5) 44 (18.0)
Leading to death 2 (0.4) 1 (0.4)
Most common adverse events†
Anemia
Any grade 307 (63.4) 43 (17.6)
Grade ≥3 150 (31.0) 4 (1.6)
Nausea
Any grade 278 (57.4) 67 (27.5)
Grade ≥3 6 (1.2) 2 (0.8)
Thrombocytopenia
Any grade 222 (45.9) 9 (3.7)
Grade ≥3 139 (28.7) 1 (0.4)
Constipation
Any grade 189 (39.0) 46 (18.9)
Grade ≥3 1 (0.2) 0
Fatigue
Any grade 168 (34.7) 72 (29.5)
Grade ≥3 9 (1.9) 1 (0.4)
Platelet count decreased
Any grade 133 (27.5) 3 (1.2)
Grade ≥3 63 (13.0) 0
Neutropenia
Any grade 128 (26.4) 16 (6.6)
Grade ≥3 62 (12.8) 3 (1.2)
Headache
Any grade 126 (26.0) 36 (14.8)
Grade ≥3 2 (0.4) 0
Insomnia
Any grade 119 (24.6) 35 (14.3)
Grade ≥3 4 (0.8) 1 (0.4)
Vomiting
Any grade 108 (22.3) 29 (11.9)
Grade ≥3 4 (0.8) 2 (0.8)
Abdominal pain
Any grade 106 (21.9) 75 (30.7)
Grade ≥3 7 (1.4) 1 (0.4)
*  The determination of whether an adverse event was related to a trial treatment
was made by the investigator.
†  The most common adverse events were reported in at least 20% of the patients 
in the niraparib group and are listed in descending order of frequency.
Table 2. Adverse Events.
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ally considered to have incurable disease with 
chemotherapy alone. Niraparib extends treatment 
beyond chemotherapy and provides a sustained 
progression-free survival benefit for those at risk 
for early relapse, including the one third of pa-
tients who had a partial response to platinum-
based chemotherapy (8.3 months vs. 5.6 months 
with placebo; hazard ratio, 0.60). Niraparib also 
prolonged the time without progression or death 
in the patients who had a complete response 
after chemotherapy (16.4 months vs. 9.5 months; 
hazard ratio, 0.60). Notably, at 18 months after 
randomization and 2 years after the diagnosis of 
advanced ovarian cancer, Kaplan–Meier analysis 
estimated that in the niraparib group, 59% of 
the patients who had tumors with homologous-
recombination deficiency and 42% of the overall 
population were alive without disease progres-
sion, as compared with 35% and 28% of pa-
tients, respectively, in the placebo group. This 
treatment effect occurred without a decrement 
in quality of life, as assessed by patient-reported 
outcomes.
The clinical benefit of niraparib in the overall 
population was not driven only by the subgroup 
of patients with BRCA mutations. In the patients 
who had tumors with homologous-recombina-
tion deficiency, niraparib provided a significant 
clinical benefit over placebo with respect to the 
median duration of progression-free survival both 
in patients with BRCA mutations (22.1 months 
vs. 10.9 months; hazard ratio, 0.40) and in those 
without BRCA mutations (19.6 months vs. 8.2 
months; hazard ratio, 0.50). In the subgroup of 
patients with homologous-recombination profi-
ciency, the longer median duration of progres-
sion-free survival in the niraparib group than in 
the placebo group (8.1 months vs. 5.4 months; 
hazard ratio, 0.68) supports the hypothesis that 
niraparib has mechanisms of action other than 
those involved in the repair of DNA damage. 
Complementary mechanisms of action for nirap-
arib, including PARP-regulated gene transcrip-
tion, ribosome biogenesis, and immune activa-
tion, may explain this clinical observation.21,22 
These analyses suggest that treatment with ni-
raparib after first-line platinum-based chemo-
therapy extends benefit to all patients. The 
sensitivity to niraparib is lower in patients who 
have tumors with homologous-recombination 
proficiency than in those who have tumors with 
homologous-recombination deficiency.
The use of olaparib as a first-line treatment is 
limited to patients with BRCA mutations, as it 
was assessed in the SOLO1 trial.4 Notable differ-
ences exist between the SOLO1 and PRIMA 
populations. In the PRIMA trial, we enrolled 
patients who had nonmutated BRCA ovarian can-
cer. Patients in SOLO1 were at lower risk for 
disease progression or death as evidenced by 
prognostic factors, since more patients in SOLO1 
than in PRIMA had stage III disease (83% vs. 
65%) and fewer received neoadjuvant chemo-
therapy (35% vs. 67%). Most patients with stage 
III ovarian cancer in SOLO1 underwent primary 
debulking surgery and had no visible residual 
disease (44%, vs. 0.4% in PRIMA). These factors 
influence outcomes and may explain the ob-
served between-trial differences in the median 
duration of progression-free survival. Subgroup 
analysis of the data from SOLO1 showed that in 
the patients with residual disease after debulk-
ing surgery, the treatment effect of olaparib 
(progression-free survival of 29.4 months with 
olaparib vs. 11.3 months with placebo; hazard 
ratio, 0.44; 95% CI, 0.25 to 0.77) was similar to 
that of niraparib in patients with BRCA mutations 
and residual disease in PRIMA (22.1 months 
with niraparib vs. 10.9 months with placebo; 
hazard ratio, 0.40; 95% CI, 0.27 to 0.62).23
At the time that we designed the PRIMA trial, 
bevacizumab had not been approved for first-
line treatment in all participating countries, and 
many patients receiving first-line therapy are in-
eligible to receive bevacizumab because of safety 
concerns or limited data regarding first-line use. 
The PRIMA trial provides data on the benefit of 
niraparib in patients with advanced ovarian can-
cer who were receiving neoadjuvant chemother-
apy, a population of patients who have not been 
included in the phase 3 trials of bevacizumab 
(GOG-218 and ICON7)2,3 and who have limited 
or no treatment options beyond chemotherapy. 
Among the two thirds of patients in the PRIMA 
trial who received neoadjuvant chemotherapy, 
the receipt of niraparib was associated with a 
41% lower relative risk of disease progression or 
death than placebo.
Most of the patients receiving niraparib or 
placebo had an adverse event during the trial. 
The frequency of adverse events was greater in 
the niraparib group than in the placebo group, 
which was consistent with the class effects of 
PARP inhibitors. Myelosuppression events were 
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managed with treatment interruptions and dose 
reductions. Treatment discontinuations occurred 
in 4.3% of the patients in the niraparib group 
because of thrombocytopenia, a finding that 
was consistent with the results of the NOVA 
trial. Other adverse events that have been as-
sociated with PARP inhibitors, including nau-
sea and fatigue, were of low grade. One patient 
in the nira parib group received the diagno-
sis of myelodysplastic syndrome in the context 
of bowel perforation, sepsis, and progressive 
disease.
We found that among patients with newly 
diagnosed advanced ovarian cancer, those who 
received daily oral therapy with the PARP inhibi-
tor niraparib after a response to platinum-based 
chemotherapy had a significantly longer duration 
of progression-free survival than those who re-
ceived placebo. There was a higher frequency of 
myelosuppression and low-grade nausea in the 
niraparib group than in the placebo group.
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